litlas
Log inCreate account

James Chih‐Hsin Yang

Active 1988–2025

Also published as
James Chih-Hsin Yang · James Chih Hsin Yang
305
Papers
85,549
Citations
133
h-index
292
i10-index

Citations

Citations per year for James Chih‐Hsin Yang1989: 6 citations1990: 23 citations1991: 21 citations1992: 25 citations1993: 39 citations1994: 45 citations1995: 50 citations1996: 50 citations1997: 60 citations1998: 84 citations1999: 132 citations2000: 132 citations2001: 134 citations2002: 125 citations2003: 168 citations2004: 253 citations2005: 264 citations2006: 322 citations2007: 420 citations2008: 438 citations2009: 404 citations2010: 434 citations2011: 376 citations2012: 465 citations2013: 655 citations2014: 572 citations2015: 874 citations2016: 905 citations2017: 1,114 citations2018: 1,226 citations2019: 3,158 citations2020: 3,232 citations2021: 3,394 citations2022: 2,694 citations2023: 2,059 citations2024: 3,337 citations2025: 1,954 citations2026: 42 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,870 citing papers, 28.4% of this breakdownChina: 3,738 citing papers, 13.5% of this breakdownItaly: 1,355 citing papers, 4.9% of this breakdownUnited Kingdom: 1,278 citing papers, 4.6% of this breakdownGermany: 1,255 citing papers, 4.5% of this breakdownJapan: 1,211 citing papers, 4.4% of this breakdownFrance: 1,114 citing papers, 4% of this breakdownSpain: 827 citing papers, 3% of this breakdownCanada: 752 citing papers, 2.7% of this breakdownNetherlands: 751 citing papers, 2.7% of this breakdownSouth Korea: 695 citing papers, 2.5% of this breakdownSwitzerland: 648 citing papers, 2.4% of this breakdown
0%28.4%Other 22.4%

Institutions

Fields

  • Medicine69.6%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Immunology and Microbiology13.1%
  • Engineering0.6%
  • Chemistry0.5%
  • Materials Science0.4%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers10.5%
  • Lung Cancer Treatments and Mutations9.6%
  • Immunotherapy and Immune Responses7.9%
  • CAR-T cell therapy research6.9%
  • Lung Cancer Research Studies4.7%
  • Immune Cell Function and Interaction4.2%
  • Other56.2%

Coauthors

All papers

Open in search
  1. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

    Authors: David Planchard, Pasi A. Jänne, Ying Cheng, James Chih‐Hsin Yang, Noriko Yanagitani, Sang‐We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut Lucien Geater, К. К. Лактионов, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, Igor Andrašina, Jonathan W. Goldman, Dana Ghiorghiu, Yuri Rukazenkov, Alex Todd, Kunihiko Kobayashi - New England Journal of Medicine 2023 cited by 650

  2. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

    Authors: Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, James Chih Hsin Yang, Fabrice Barlési, Dae Ho Lee, Luis Paz Ares, Robert W. Hsieh, Namrata S. Patil, Patrick J. Twomey, Xiaoying Yang, Raymond D. Meng, Melissa L. Johnson - The Lancet Oncology 2022 cited by 424

  3. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    Authors: Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander I. Spira, Tsung‐Ying Yang, Dong‐Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, José Trigo, Kōichi Goto, Jong‐Seok Lee, James Chih‐Hsin Yang, Ramaswamy Govindan, Joshua Bauml, Pilar Garrido, Matthew Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish‐Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 cited by 632

  4. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

    Authors: Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley - Clinical Cancer Research 2011 cited by 2,120

  5. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Authors: Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le - New England Journal of Medicine 2020 cited by 854

  6. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  7. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

    Authors: Steven A. Rosenberg, Beverly S. Packard, Paul Aebersold, Diane Solomon, Suzanne L. Topalian, Stephen T. Toy, Paul Simon, Michael T. Lotze, James Chih‐Hsin Yang, Claudia A. Seipp, Colleen Simpson, Charles W. Carter, Steven Bock, Douglas J. Schwartzentruber, John P. Wei, Donald E. White - New England Journal of Medicine 1988 cited by 2,345

  8. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

    Authors: Kōichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Chih‐Hsi S. Kuo, James Chih‐Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 299

  9. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Authors: Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler - Journal of Clinical Oncology 2013 cited by 3,198

  10. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

    Authors: Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, Mirjana Wollner, James Chih‐Hsin Yang, Julien Mazières, Francesco Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, Hye Ryun Kim, on behalf of the KEYNOTE-604 Investigators - Journal of Clinical Oncology 2020 cited by 759

  11. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Authors: Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih‐Hsin Yang, Martin Reck, Kiyotaka Yoh, Se‐Hoon Lee, Luis Paz‐Ares, Benjamin Besse, Paolo Bironzo, Dong‐Wan Kim, Melissa L. Johnson, Yi‐Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D. Patel, Egbert F. Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang‐Dian Fan, Parul Patel, Andrea Sporchia, David Sternberg, Dalila Sellami, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 225

  12. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    Authors: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat - New England Journal of Medicine 2018 cited by 976

  13. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    Authors: Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 cited by 375

  14. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

    Authors: Alena Gros, Paul F. Robbins, Xin Yao, Yong F. Li, Simon Turcotte, Eric Tran, John R. Wunderlich, Arnold Mixon, Shawn Farid, Mark E. Dudley, Ken‐ichi Hanada, Jorge R. Almeida, Samuel Darko, Daniel C. Douek, James Chih‐Hsin Yang, Steven A. Rosenberg - Journal of Clinical Investigation 2014 cited by 1,108

  15. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Authors: Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. Ramalingam, Myung‐Ju Ahn, Sang-We Kim, Wu‐Chou Su, Leora Horn, Daniel Haggstrom, Enriqueta Felip, Joo-Hang Kim, Paul Frewer, Mireille Cantarini, Kathryn H. Brown, Paul A. Dickinson, Serban Ghiorghiu, Malcolm Ranson - New England Journal of Medicine 2015 cited by 2,111

  16. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

    Authors: Pasi A. Jänne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu - Cancer Discovery 2021 cited by 287

  17. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih‐Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz‐Ares - Journal of Hematology & Oncology 2023 cited by 157

  18. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Authors: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat - Journal of Thoracic Oncology 2021 cited by 372

  19. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

    Authors: Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda Rogers-Freezer, Sharon Mavroukakis, Steven A. Rosenberg - Science 2006 cited by 2,586

  20. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

    Authors: Richard A. Morgan, Nachimuthu Chinnasamy, Daniel Abate‐Daga, Alena Gros, Paul F. Robbins, Zhili Zheng, Mark E. Dudley, Steven A. Feldman, James Chih‐Hsin Yang, Richard M. Sherry, Giao Q. Phan, Marybeth S. Hughes, Udai S. Kammula, Akemi D. Miller, Crystal J. Hessman, Ashley A. Stewart, Nicholas P. Restifo, Martha Quezado, Meghna Alimchandani, Avi Z. Rosenberg, Avindra Nath, Tongguang Wang, Bibiana Bielekova, Simone C. Wuest, Nirmala Akula, Francis J. McMahon, Susanne Wilde, Barbara Mosetter, Dolores J. Schendel, Carolyn M. Laurençot, Steven A. Rosenberg - Journal of Immunotherapy 2013 cited by 1,145

  21. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

    Authors: Shun Lu, Terufumi Kato, Xiaorong Dong, Myung‐Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih‐Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduardo Cronemberger, Toshiaki Takahashi, Y. Runglodvatana, Ming Chen, Xiangning Huang, Ellie Grainger, Dana Ghiorghiu, Toon van der Gronde, Suresh S. Ramalingam - New England Journal of Medicine 2024 cited by 295

  22. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Authors: Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih‐Hsin Yang, Ki Hyeong Lee, Shun Lü, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong‐Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Scott A. Laurie, Chun-Ming Tsai, Mehdi Shahidi, Miyoung Kim, Dan Massey, Victoria Zazulina, Luis Paz‐Ares - The Lancet Oncology 2016 cited by 1,175

  23. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

    Authors: Sanja Stevanović, Lindsey M. Draper, Michelle M. Langhan, Tracy E. Campbell, Mei Li M. Kwong, John R. Wunderlich, Mark E. Dudley, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Nicholas P. Restifo, Steven A. Rosenberg, Christian S. Hinrichs - Journal of Clinical Oncology 2015 cited by 677

  24. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Authors: Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James Chih‐Hsin Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Yong F. Li, Mona El‐Gamil, Steven A. Rosenberg - Clinical Cancer Research 2014 cited by 801